IN2015DN00735A - - Google Patents
Info
- Publication number
- IN2015DN00735A IN2015DN00735A IN735DEN2015A IN2015DN00735A IN 2015DN00735 A IN2015DN00735 A IN 2015DN00735A IN 735DEN2015 A IN735DEN2015 A IN 735DEN2015A IN 2015DN00735 A IN2015DN00735 A IN 2015DN00735A
- Authority
- IN
- India
- Prior art keywords
- treatment
- cancer
- formula
- derivative compound
- aromatase inhibitor
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 3
- 229940122815 Aromatase inhibitor Drugs 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 2
- 239000003886 aromatase inhibitor Substances 0.000 abstract 2
- 125000003917 carbamoyl group Chemical class [H]N([H])C(*)=O 0.000 abstract 2
- -1 urea derivative compound Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to a pharmaceutical combination comprising a 2 carboxamide cycloamino urea derivative compound of formula (I) and at least one aromatase inhibitor for the treatment of cancer; the uses of such combinations in the treatment of cancer; and to a method of treating warm blooded animals including humans suffering cancer by administering to said animal in need of such treatment an effective dose of a 2 carboxamide cycloamino urea derivative compound of formula (I) in combination with at least one aromatase inhibitor.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261703533P | 2012-09-20 | 2012-09-20 | |
| US201261708070P | 2012-10-01 | 2012-10-01 | |
| PCT/US2013/060292 WO2014047109A1 (en) | 2012-09-20 | 2013-09-18 | Pharmaceutical combination comprising a phosphatidylinositol 3-kinase inhibitor|and an aromatase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN00735A true IN2015DN00735A (en) | 2015-07-10 |
Family
ID=49263471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN735DEN2015 IN2015DN00735A (en) | 2012-09-20 | 2013-09-18 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9532982B2 (en) |
| EP (1) | EP2897644B1 (en) |
| JP (1) | JP6212563B2 (en) |
| KR (1) | KR102220965B1 (en) |
| CN (1) | CN104661681B (en) |
| AU (1) | AU2013318205B2 (en) |
| BR (1) | BR112015004152A2 (en) |
| CA (1) | CA2880506C (en) |
| CY (1) | CY1120984T1 (en) |
| DK (1) | DK2897644T3 (en) |
| ES (1) | ES2686689T3 (en) |
| HR (1) | HRP20181413T1 (en) |
| HU (1) | HUE040520T2 (en) |
| IN (1) | IN2015DN00735A (en) |
| LT (1) | LT2897644T (en) |
| MX (1) | MX356278B (en) |
| PL (1) | PL2897644T3 (en) |
| PT (1) | PT2897644T (en) |
| RU (1) | RU2651023C2 (en) |
| SI (1) | SI2897644T1 (en) |
| WO (1) | WO2014047109A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3842554B1 (en) * | 2014-05-09 | 2022-12-14 | Memorial Sloan Kettering Cancer Center | Biomarkers for response to pi3k inhibitors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011506563A (en) * | 2007-12-20 | 2011-03-03 | ノバルティス アーゲー | Bisthiazole derivatives, process for their preparation and their use as pharmaceuticals |
| AU2008340053A1 (en) * | 2007-12-20 | 2009-07-02 | Novartis Ag | Thiazole derivatives used as PI 3 kinase inhibitors |
| EP2311842A3 (en) * | 2008-06-24 | 2011-07-13 | Takeda Pharmaceutical Company Limited | PI3K/M TOR inhibitors |
| UA104147C2 (en) | 2008-09-10 | 2014-01-10 | Новартис Аг | Pyrrolidine dicarboxylic acid derivative and use thereof in the treatment of proliferative diseases |
| US8293753B2 (en) * | 2009-07-02 | 2012-10-23 | Novartis Ag | Substituted 2-carboxamide cycloamino ureas |
-
2013
- 2013-09-18 RU RU2015111171A patent/RU2651023C2/en active
- 2013-09-18 BR BR112015004152A patent/BR112015004152A2/en not_active IP Right Cessation
- 2013-09-18 EP EP13770771.7A patent/EP2897644B1/en active Active
- 2013-09-18 CA CA2880506A patent/CA2880506C/en active Active
- 2013-09-18 DK DK13770771.7T patent/DK2897644T3/en active
- 2013-09-18 LT LTEP13770771.7T patent/LT2897644T/en unknown
- 2013-09-18 HU HUE13770771A patent/HUE040520T2/en unknown
- 2013-09-18 IN IN735DEN2015 patent/IN2015DN00735A/en unknown
- 2013-09-18 KR KR1020157006708A patent/KR102220965B1/en active IP Right Grant
- 2013-09-18 US US14/429,367 patent/US9532982B2/en active Active
- 2013-09-18 PT PT13770771T patent/PT2897644T/en unknown
- 2013-09-18 CN CN201380049140.1A patent/CN104661681B/en active Active
- 2013-09-18 AU AU2013318205A patent/AU2013318205B2/en active Active
- 2013-09-18 PL PL13770771T patent/PL2897644T3/en unknown
- 2013-09-18 SI SI201331154T patent/SI2897644T1/en unknown
- 2013-09-18 MX MX2015003657A patent/MX356278B/en active IP Right Grant
- 2013-09-18 JP JP2015533141A patent/JP6212563B2/en active Active
- 2013-09-18 ES ES13770771.7T patent/ES2686689T3/en active Active
- 2013-09-18 WO PCT/US2013/060292 patent/WO2014047109A1/en active Application Filing
-
2018
- 2018-09-03 HR HRP20181413TT patent/HRP20181413T1/en unknown
- 2018-09-05 CY CY181100927T patent/CY1120984T1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013318205B2 (en) | 2016-05-19 |
| JP2015532927A (en) | 2015-11-16 |
| AU2013318205A1 (en) | 2015-02-26 |
| MX2015003657A (en) | 2015-06-05 |
| HUE040520T2 (en) | 2019-03-28 |
| EP2897644B1 (en) | 2018-06-06 |
| KR20150056778A (en) | 2015-05-27 |
| JP6212563B2 (en) | 2017-10-11 |
| RU2015111171A (en) | 2016-11-10 |
| LT2897644T (en) | 2018-09-25 |
| CY1120984T1 (en) | 2019-12-11 |
| US9532982B2 (en) | 2017-01-03 |
| WO2014047109A1 (en) | 2014-03-27 |
| CA2880506A1 (en) | 2014-03-27 |
| ES2686689T3 (en) | 2018-10-19 |
| HRP20181413T1 (en) | 2018-10-19 |
| CN104661681B (en) | 2018-07-03 |
| SI2897644T1 (en) | 2018-10-30 |
| BR112015004152A2 (en) | 2017-07-04 |
| EP2897644A1 (en) | 2015-07-29 |
| KR102220965B1 (en) | 2021-02-26 |
| US20150231124A1 (en) | 2015-08-20 |
| PT2897644T (en) | 2018-10-16 |
| MX356278B (en) | 2018-05-22 |
| PL2897644T3 (en) | 2018-11-30 |
| CA2880506C (en) | 2021-04-20 |
| DK2897644T3 (en) | 2018-09-10 |
| RU2651023C2 (en) | 2018-04-18 |
| CN104661681A (en) | 2015-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201290919A1 (en) | INDASOLIC COMPOUNDS AND THEIR APPLICATION | |
| MX2021015234A (en) | Compositions and methods comprising bupropion or related compounds and dextromethorphan. | |
| MX2017009571A (en) | Heterocyclic itk inhibitors for treating inflammation and cancer. | |
| PH12016500511A1 (en) | Selective grp94 inhibitors and uses thereof | |
| MX2015012866A (en) | Pyridazinone compounds and methods for the treatment of cystic fibrosis. | |
| BR112015009168A2 (en) | compound of formula xi, use of a compound, pharmaceutical composition, method of treating a pde4-mediated disease in a subject, method of modulating a pde4-mediated function in a subject, method of achieving an effect in a patient, and method to inhibit pde4 | |
| MY166014A (en) | Combination therapy methods for treating proliferative diseases | |
| BR112015026297A2 (en) | combination therapy consisting of a tor kinase inhibitor and a substituted 5-quinazolinone compound for cancer treatment | |
| NZ729643A (en) | Combination therapy for treating cancer | |
| EA201690745A1 (en) | METHODS OF TREATMENT AND PREVENTION OF THE DISEASE "TRANSPLANTATE AGAINST THE OWNER" | |
| EA201691155A1 (en) | COMBINATION INHIBITORS OF HISTONDEACETYLASE AND IMMUNOMODULATING MEDICINES | |
| SG10201810401RA (en) | Pharmaceutical combinations for treating cancer | |
| MX2014002171A (en) | Combination treatments for hepatitis c. | |
| PH12016502352A1 (en) | Pharmaceutical composition | |
| MX2013003638A (en) | Combination treatment for rosacea. | |
| EA201491500A1 (en) | FIBROZA TREATMENT METHODS | |
| MX2022015141A (en) | Compositions and methods of use of an inappetance-controlling compound. | |
| MX2016001536A (en) | Piperidine urea derivatives. | |
| MX2015012455A (en) | Method for the treatment of fatty liver disease. | |
| UA112418C2 (en) | THERAPEUTIC DISEASE | |
| BR112012025879A2 (en) | triazole compounds as ksp inhibitors | |
| IN2015DN00735A (en) | ||
| MX2014004559A (en) | 2 - carboxamide cycloamino urea derivatives in combination with hsp90 inhibitors for the treatment of proliferative diseases. | |
| WO2014004664A3 (en) | Treatment of meningiomas using phenylbenzothiazole, stilbene, biphenylalkyne, or pyridine derivatives | |
| WO2011128434A3 (en) | Treatment of endocrine resistant breast cancer |